Table 2.
Renal endpoints for PARADIGM-HF trial; modified and adapted version [20]
ACEI angiotensin-converting enzyme inhibitor (enalapril), ARNI angiotensin receptor/neprilysin inhibitor (sacubitril/valsartan), eGFR estimated glomerular filtration rate